Literature DB >> 20434554

Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7.

Jerri do Carmo Caldeira1, Alexander Medford, Rhonda C Kines, Christopher A Lino, John T Schiller, Bryce Chackerian, David S Peabody.   

Abstract

The immunogenicity of an antigen can be dramatically increased by displaying it in a dense, multivalent context, such as on the surface of a virus or virus-like particle (VLP). Here we describe a highly versatile VLP platform for peptide display based on VLPs of the RNA bacteriophage PP7. We show that this platform can be used for the engineered display of specific peptide sequences as well as for the construction of random peptide libraries. Peptides representing the FLAG epitope, the V3 loop of HIV gp120, and a broadly cross-type neutralizing epitope from L2, the minor capsid protein of Human Papillomavirus type 16 (HPV16), were inserted into an exposed surface loop of a form of PP7 coat protein in which the two identical polypeptides of coat were fused together to form a single-chain dimer. The recombinant proteins assembled into VLPs, displayed these peptides on their surfaces, and induced high-titer antibody responses. The single-chain dimer was also highly tolerant of random 6-, 8-, and 10-amino acid insertions. PP7 VLPs displaying the HPV16 L2 epitope generated robust anti-HPV16 L2 serum antibodies after intramuscular injection that protected mice from genital infection with HPV16 pseudovirus as well as a heterologous HPV pseudovirus type, HPV45. Thus, PP7 VLPs are well-suited for the display of a wide diversity of peptides in a highly immunogenic format.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20434554      PMCID: PMC2881612          DOI: 10.1016/j.vaccine.2010.04.049

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  53 in total

1.  Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.

Authors:  Theodora Fifis; Anita Gamvrellis; Blessing Crimeen-Irwin; Geoffrey A Pietersz; Jie Li; Patricia L Mottram; Ian F C McKenzie; Magdalena Plebanski
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

2.  The influence of antigen organization on B cell responsiveness.

Authors:  M F Bachmann; U H Rohrer; T M Kündig; K Bürki; H Hengartner; R M Zinkernagel
Journal:  Science       Date:  1993-11-26       Impact factor: 47.728

3.  Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.

Authors:  Diana V Pastrana; Ratish Gambhira; Christopher B Buck; Yuk-Ying S Pang; Cynthia D Thompson; Timothy D Culp; Neil D Christensen; Douglas R Lowy; John T Schiller; Richard B S Roden
Journal:  Virology       Date:  2005-07-05       Impact factor: 3.616

4.  Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles.

Authors:  B Chackerian; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

5.  Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

Authors:  Ratish Gambhira; Subhashini Jagu; Balasubramanyam Karanam; Patti E Gravitt; Timothy D Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

6.  Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice.

Authors:  Fu-Shi Quan; Aswani Vunnava; Richard W Compans; Sang-Moo Kang
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

7.  Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.

Authors:  Jeffrey N Roberts; Christopher B Buck; Cynthia D Thompson; Rhonda Kines; Marcelino Bernardo; Peter L Choyke; Douglas R Lowy; John T Schiller
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

8.  Role of repetitive antigen patterns for induction of antibodies against antibodies.

Authors:  T Fehr; M F Bachmann; E Bucher; U Kalinke; F E Di Padova; A B Lang; H Hengartner; R M Zinkernagel
Journal:  J Exp Med       Date:  1997-05-19       Impact factor: 14.307

9.  Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

Authors:  Subhashini Jagu; Balasubramanyam Karanam; Ratish Gambhira; Sudha V Chivukula; Revathi J Chaganti; Douglas R Lowy; John T Schiller; Richard B S Roden
Journal:  J Natl Cancer Inst       Date:  2009-05-26       Impact factor: 13.506

10.  Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops.

Authors:  Katharina Slupetzky; Saeed Shafti-Keramat; Petra Lenz; Sabine Brandt; Andreas Grassauer; Margit Sara; Reinhard Kirnbauer
Journal:  J Gen Virol       Date:  2001-11       Impact factor: 3.891

View more
  47 in total

1.  A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.

Authors:  Patricia M Day; Yuk-Ying S Pang; Rhonda C Kines; Cynthia D Thompson; Douglas R Lowy; John T Schiller
Journal:  Clin Vaccine Immunol       Date:  2012-05-16

Review 2.  Progress and prospects for L2-based human papillomavirus vaccines.

Authors:  Rosie T Jiang; Christina Schellenbacher; Bryce Chackerian; Richard B S Roden
Journal:  Expert Rev Vaccines       Date:  2016-03-10       Impact factor: 5.217

3.  Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.

Authors:  Ebenezer Tumban; Pavan Muttil; Carolina Andrea A Escobar; Julianne Peabody; Denis Wafula; David S Peabody; Bryce Chackerian
Journal:  Vaccine       Date:  2015-05-21       Impact factor: 3.641

Review 4.  Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine design.

Authors:  Rosalynn L Ord; Marilis Rodriguez; Cheryl A Lobo
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Phage display--a powerful technique for immunotherapy: 2. Vaccine delivery.

Authors:  Justyna Bazan; Ireneusz Całkosiński; Andrzej Gamian
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

Review 6.  Virus-like particles for the prevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Richard B S Roden
Journal:  Expert Rev Vaccines       Date:  2013-02       Impact factor: 5.217

Review 7.  Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform.

Authors:  John P O'Rourke; David S Peabody; Bryce Chackerian
Journal:  Curr Opin Virol       Date:  2015-03-29       Impact factor: 7.090

8.  Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.

Authors:  Somayeh Pouyanfard; Gloria Spagnoli; Lorenzo Bulli; Kathrin Balz; Fan Yang; Caroline Odenwald; Hanna Seitz; Filipe C Mariz; Angelo Bolchi; Simone Ottonello; Martin Müller
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

Review 9.  Virus-Based Nanoparticles as Versatile Nanomachines.

Authors:  Kristopher J Koudelka; Andrzej S Pitek; Marianne Manchester; Nicole F Steinmetz
Journal:  Annu Rev Virol       Date:  2015-09-25       Impact factor: 10.431

10.  Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.

Authors:  Mitchell Tyler; Ebenezer Tumban; Agnieszka Dziduszko; Michelle A Ozbun; David S Peabody; Bryce Chackerian
Journal:  Vaccine       Date:  2014-06-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.